摘要
目的 观察吉非替尼(gefitinib,ZD1839)治疗化疗失败的晚期非小细胞肺癌的疗效及毒副反应。方法 2003年4月至2006年6月用吉非替尼治疗化疗失败的晚期非小细胞肺癌38例,服药至疾病进展或出现不可耐受的毒副反应。结果 38例均可评价疗效,获得CR 0例,PR 8例(21.05%),SD 18例(47.37%),疾病控制率为68.42%,PD 12例(31.57%);中位生存时间7个月(1~26个月),中位疾病进展时间4.5个月,与药物相关的毒副反应为:皮疹19例(50%)、恶心10例(26.3%)、腹泻9例(23.68%)、皮肤干燥5例(13.16%)、乏力3例(7.89%),其它如发热、口腔溃疡及关节痛等毒副反应发生率均〈5%,实验室指标末见明显异常。结论 吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效好,毒副反应少,耐受性好,可提高患者生活质量,延长生存期。
Objective To observe the efficacy and drug-related toxicity of gefitinib(ZD1839) in the treatment of the 38 cases with advanced non-small cell lung cancer who failed to respond previous chemotherapy. Methods Thirty-eight non-small cell lung cancer patients who failed to respond previous chemotherapy were treated from Apr. 2003 to Jun. 2006. Gefitinib was given as a single drug at a dose of 250 mg per day orally until disease progressed or unaceeptable toxicity occurred. Results Among these 38 patients, complete response 0 (0%) , partial response 8 (21.05%) , stable disease 18 (47.37%) , disease control rate 68.42% , progressive disease 12 (31.5"7%). Median survival time of the entire group was 7 months ( 1 - 26 months). Median time to progression was 4.5 months. The drug-related adverse reactions are skin rash 19 (50%), nausea 10 (26.3%), diarrhea9 (23.68%), xerosis curls5 (13. 16%), fatigue3 (7.89%). The rates of adverse reactions such as fever, dental ulcer and arthralgia were bellow 5%. The breadboard index is normal. Conclusions Gefitinib is an effective drug in the treatment of the cases with advanced non-small cell lung cancer who failed to respond previous chemotherapy. The toxicity can be well acceptable.
出处
《肿瘤基础与临床》
2007年第5期390-392,共3页
journal of basic and clinical oncology
基金
江苏省科技发展计划项目(编号:BS2006005)
关键词
吉非替尼
非小细胞肺癌
化疗
Gefitinib(ZD1839)
non-small cell lung cancer
ehemotherapy